| 今开：12.35 | 昨收：12.35 |
| 最高：12.9125 | 最低：12.31 |
| 涨停价：0.0 | 跌停价：0.0 |
| 总市值：6.21801603E8 |
Cabaletta Bio(CABA)04-23 19:15
$Cabaletta Bio(CABA)$ DEFA14A Additional definitive proxy soliciting materials and Rule 14(a)(12) material Accession Number: 0001193125-24-105890 Act: 34 Size: 162 KB 网页链接查看全文
Cabaletta Bio(CABA)04-23 19:05
$Cabaletta Bio(CABA)$ DEF 14A Other definitive proxy statements Accession Number: 0001193125-24-105870 Act: 34 Size: 624 KB 网页链接查看全文
Cabaletta Bio(CABA)03-05 06:55
$Cabaletta Bio(CABA)$ 4 Statement of changes in beneficial ownership of securities Accession Number: 0000950170-24-025027 Size: 5 KB 网页链接查看全文
Cabaletta Bio(CABA)05-15 19:55
$Cabaletta Bio(CABA)$ 10-Q Quarterly report [Sections 13 or 15(d)] Accession Number: 0000950170-24-060045 Act: 34 Size: 7 MB 网页链接查看全文
Cabaletta Bio(CABA)05-15 19:15
$Cabaletta Bio(CABA)$ 8-K Current report, items 2.02, 7.01, and 9.01 Accession Number: 0001193125-24-138874 Act: 34 Size: 10 MB 网页链接查看全文
Cabaletta Bio(CABA)03-05 06:45
$Cabaletta Bio(CABA)$ 4 Statement of changes in beneficial ownership of securities Accession Number: 0000950170-24-025002 Size: 5 KB 网页链接查看全文
Cabaletta Bio(CABA)03-05 06:55
$Cabaletta Bio(CABA)$ 4 Statement of changes in beneficial ownership of securities Accession Number: 0000950170-24-025039 Size: 5 KB 网页链接查看全文
Cabaletta Bio(CABA)03-21 19:55
$Cabaletta Bio(CABA)$ S-8 Securities to be offered to employees in employee benefit plans Accession Number: 0001193125-24-073318 Act: 33 Size: 55 KB 网页链接查看全文
Cabaletta Bio(CABA)03-21 19:15
$Cabaletta Bio(CABA)$ 8-K Current report, items 2.02 and 9.01 Accession Number: 0001193125-24-073294 Act: 34 Size: 224 KB 网页链接查看全文
Cabaletta Bio(CABA)03-21 19:35
$Cabaletta Bio(CABA)$ 10-K Annual report [Section 13 and 15(d), not S-K Item 405] Accession Number: 0000950170-24-034422 Act: 34 Size: 10 MB 网页链接查看全文
二麻麻04-08 22:02
$Cabaletta Bio(CABA)$
From Fred Alger Management: Cabaletta是一家临床阶段的生物技术公司，专注于发现和开发自身免疫性疾病的靶向细胞疗法。
该公司的主要候选药物 CABA-201 是一种治疗狼疮和肌炎的细胞疗法，美国食品和药物管理局已接受 CABA-201 的新药申请，为 1/2 期的初步读数...查看全文
产业链观察2022-10-11 19:19
药闻▶2022年10月11日，中国南京和上海，美国宾夕法尼亚州费城和加利福尼亚州圣何塞，——驯鹿生物（“IASO Bio”），一家处于临床阶段、致力于细胞创新药物开发的生物制药公司与$Cabaletta Bio(CABA)$ ，一家致力于针对自身免疫性疾病患者开发和商业化的首个靶向细胞疗法的临床阶段...查看全文
$Cabaletta Bio(CABA)$ 8-K Current report, items 7.01, 8.01, and 9.01 Accession Number: 0001193125-23-146067 Act: 34 Size: 14 MB 网页链接
$Cabaletta Bio(CABA)$ 8-K Current report, items 7.01 and 9.01 Accession Number: 0001193125-23-145622 Act: 34 Size: 179 KB 网页链接
$Cabaletta Bio(CABA)$ 10-Q Quarterly report [Sections 13 or 15(d)] Accession Number: 0000950170-23-020849 Act: 34 Size: 7 MB 网页链接
$Cabaletta Bio(CABA)$ 8-K Current report, items 2.02 and 9.01 Accession Number: 0001193125-23-141371 Act: 34 Size: 207 KB 网页链接
$Cabaletta Bio(CABA)$ 8-K Current report, items 7.01, 8.01, and 9.01 Accession Number: 0001193125-23-132565 Act: 34 Size: 196 KB 网页链接
$Cabaletta Bio(CABA)$ 8-K Current report, items 7.01, 8.01, and 9.01 Accession Number: 0001193125-23-128724 Act: 34 Size: 13 MB 网页链接
$Cabaletta Bio(CABA)$ EFFECT Notice of Effectiveness Accession Number: 9999999995-23-001056 Act: 33 Size: 1 KB 网页链接
$Cabaletta Bio(CABA)$ ARS Annual Report to Security Holders Accession Number: 0001193125-23-109213 Act: 34 Size: 7 MB 网页链接
$Cabaletta Bio(CABA)$ DEF 14A Other definitive proxy statements Accession Number: 0001193125-23-109203 Act: 34 Size: 573 KB 网页链接
$Cabaletta Bio(CABA)$ DEFA14A Additional definitive proxy soliciting materials and Rule 14(a)(12) material Accession Number: 0001193125-23-109207 Act: 34 Size: 36 KB 网页链接